Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Cited In for PubMed (Select 18254653)

1.

Reduced Immune Activation During Tenofovir-Emtricitabine Therapy in HIV-Negative Individuals.

Castillo-Mancilla JR, Meditz A, Wilson C, Zheng JH, Palmer BE, Lee EJ, Gardner EM, Seifert S, Kerr B, Bushman LR, MaWhinney S, Anderson PL.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):495-501. doi: 10.1097/QAI.0000000000000529.

PMID:
25763783
2.

Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.

Massud I, Martin A, Dinh C, Mitchell J, Jenkins L, Heneine W, Pau CP, García-Lerma JG.

J Antimicrob Chemother. 2015 May;70(5):1473-81. doi: 10.1093/jac/dku556. Epub 2015 Jan 27.

PMID:
25630643
3.

Surrogates of protection in repeated low-dose challenge experiments.

Long DM, Hudgens MG, Wu CD.

Stat Med. 2015 May 10;34(10):1747-60. doi: 10.1002/sim.6436. Epub 2015 Jan 28.

PMID:
25628249
4.

Accuracy of highly sexually active gay and bisexual men's predictions of their daily likelihood of anal sex and its relevance for intermittent event-driven HIV pre-exposure prophylaxis.

Parsons JT, Rendina HJ, Grov C, Ventuneac A, Mustanski B.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):449-55. doi: 10.1097/QAI.0000000000000507.

PMID:
25559594
5.

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.

Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C; Partners PrEP Study Team.

Lancet Infect Dis. 2014 Nov;14(11):1055-64. doi: 10.1016/S1473-3099(14)70937-5. Epub 2014 Oct 7.

PMID:
25300863
6.

HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.

Garrett NJ, Werner L, Naicker N, Naranbhai V, Sibeko S, Samsunder N, Gray C, Williamson C, Morris L, Abdool-Karim Q, Abdool-Karim SS.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):55-61. doi: 10.1097/QAI.0000000000000367.

PMID:
25247433
7.

Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques.

Radzio J, Hanley K, Mitchell J, Ellis S, Deyounks F, Jenkins L, Heneine W, García-Lerma JG.

J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):365-9. doi: 10.1097/QAI.0000000000000340.

PMID:
25202923
8.

Role of the pharmacist in pre-exposure chemoprophylaxis (PrEP) therapy for HIV prevention.

Clauson KA, Polen HH, Joseph SA, Zapantis A.

Pharm Pract (Granada). 2009 Jan;7(1):11-8. Epub 2009 Mar 15.

9.

High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.

Matthews LT, Heffron R, Mugo NR, Cohen CR, Hendrix CW, Celum C, Bangsberg DR, Baeten JM; Partners PrEP Study Team.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):91-7. doi: 10.1097/QAI.0000000000000246.

10.

Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?

Yu W, Wang L, Han N, Zhang X, Mahapatra T, Mahapatra S, Babu GR, Tang W, Detels R, Zhao J.

Artif Cells Nanomed Biotechnol. 2014 Jul 31:1-8. [Epub ahead of print]

PMID:
25078629
11.

A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity.

Ross TM, Pereira LE, Luckay A, McNicholl JM, García-Lerma JG, Heneine W, Eugene HS, Pierce-Paul BR, Zhang J, Hendry RM, Smith JM.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1072-81. doi: 10.1089/AID.2014.0030. Epub 2014 Jul 29.

PMID:
24914761
12.

Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couples.

Roberts ST, Heffron R, Ngure K, Celum C, Kurth A, Curran K, Mugo N, Baeten JM.

AIDS Behav. 2014 Sep;18(9):1701-11. doi: 10.1007/s10461-014-0804-1.

PMID:
24871870
13.

Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.

Anderson PL, Glidden DV, Bushman LR, Heneine W, García-Lerma JG.

J Antimicrob Chemother. 2014 Sep;69(9):2470-6. doi: 10.1093/jac/dku162. Epub 2014 May 26.

PMID:
24862094
14.

An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda.

Psaros C, Haberer JE, Katabira E, Ronald A, Tumwesigye E, Campbell JD, Wangisi J, Mugwanya K, Kintu A, Enyakoit M, Thomas KK, Donnell D, Krows M, Kidoguchi L, Ware N, Baeten JM, Celum C, Bangsberg DR, Safren SA.

J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):522-9. doi: 10.1097/QAI.0000000000000212.

PMID:
24853311
15.

HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.

Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant RM; iPrEx Study Team.

J Infect Dis. 2014 Oct 15;210(8):1217-27. doi: 10.1093/infdis/jiu233. Epub 2014 Apr 16.

16.

Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.

Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, Russell-Lodrigue K, Bohm RP, Cheng-Mayer C, Hong Z, Markowitz M, Ho DD.

Science. 2014 Mar 7;343(6175):1151-4. doi: 10.1126/science.1248707. Epub 2014 Mar 4.

17.

Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.

Forbes CJ, McCoy CF, Murphy DJ, Woolfson AD, Moore JP, Evans A, Shattock RJ, Malcolm RK.

J Pharm Sci. 2014 May;103(5):1422-32. doi: 10.1002/jps.23913. Epub 2014 Mar 1.

PMID:
24585370
18.

Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution.

Kauffman RC, Villalobos A, Bowen JH, Adamson L, Schinazi RF.

PLoS One. 2014 Feb 5;9(2):e88258. doi: 10.1371/journal.pone.0088258. eCollection 2014.

19.

Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: a meta-analysis of randomized controlled trials.

Jiang J, Yang X, Ye L, Zhou B, Ning C, Huang J, Liang B, Zhong X, Huang A, Tao R, Cao C, Chen H, Liang H.

PLoS One. 2014 Feb 3;9(2):e87674. doi: 10.1371/journal.pone.0087674. eCollection 2014.

20.

HIV pre-exposure prophylaxis interest among female sex workers in Guangxi, China.

Ye L, Wei S, Zou Y, Yang X, Abdullah AS, Zhong X, Ruan Y, Lin X, Li M, Wu D, Jiang J, Xie P, Huang J, Liang B, Zhou B, Su J, Liang H, Huang A.

PLoS One. 2014 Jan 22;9(1):e86200. doi: 10.1371/journal.pone.0086200. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk